Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Лимфома из клеток мантии

Список литературы

  1. Swerdlow S.H. et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon, France: International Agency for Research in Cancer (IARC) / ed. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H T.J. 2017. 585 p.
  2. Campo E., Raffeld M., Jaffe E.S. Mantle-cell lymphoma. // Semin. Hematol. 1999. Vol. 36, № 2. P. 115–127.
  3. Swerdlow S.H., Williams M.E. From centrocytic to mantle cell lymphoma: a clinicopathologic and molecular review of 3 decades. // Hum. Pathol. 2002. Vol. 33, № 1. P. 7–20.
  4. Kodet R. et al. Mantle cell lymphoma: improved diagnostics using a combined approach of immunohistochemistry and identification of t(11;14)(q13;q32) by polymerase chain reaction and fluorescence in situ hybridization. // Virchows Arch. 2003. Vol. 442, № 6. P. 538–547.
  5. Navarro A. et al. Molecular Pathogenesis of Mantle Cell Lymphoma // Hematol. Oncol. Clin. North Am. Hematol Oncol Clin North Am, 2020. Vol. 34, № 5. P. 795–807.
  6. Hartmann E.M. et al. Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling // Blood. Blood, 2010. Vol. 116, № 6. P. 953–961.
  7. Iqbal J. et al. Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis // Blood. The American Society of Hematology, 2012. Vol. 119, № 21. P. 4939.
  8. Fu K. et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. // Blood. The American Society of Hematology, 2005. Vol. 106, № 13. P. 4315–4321.
  9. Wlodarska I. et al. Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas // Blood. Blood, 2008. Vol. 111, № 12. P. 5683–5690.
  10. Salaverria I. et al. CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma // Blood. Blood, 2013. Vol. 121, № 8. P. 1394–1402.
  11. Teras L.R. et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes // CA. Cancer J. Clin. CA Cancer J Clin, 2016. Vol. 66, № 6. P. 443–459.
  12. Zhou Y. et al. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004 // Cancer. Cancer, 2008. Vol. 113, № 4. P. 791–798.
  13. Fernàndez V. et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma // Cancer Res. Cancer Res, 2010. Vol. 70, № 4. P. 1408–1418.
  14. Ondrejka S.L. et al. Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis // Haematologica. Haematologica, 2011. Vol. 96, № 8. P. 1121–1127.
  15. Navarro A. et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features // Cancer Res. Cancer Res, 2012. Vol. 72, № 20. P. 5307–5316.
  16. Eskelund C.W. et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy // Blood. 2017. Vol. 130, № 17. P. 1903–1910.
  17. Jain P. et al. High-Risk Mantle Cell Lymphoma : De fi nition , Current Challenges , and Management // J. Clin. Oncol. 2020. Vol. 62. P. 56–58.
  18. Демина Е.А. et al. Общие принципы диагностики лимфом // Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. 2018. P. 9–27.
  19. Carbone P.P. et al. Report of the Committee on Hodgkin’s Disease Staging Classification // Cancer Res. 1971. Vol. 31, № 11. P. 1860–1861.
  20. Bosch F. et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. // Cancer. 1998. Vol. 82, № 3. P. 567–575.
  21. Norton A.J. et al. Mantle cell lymphoma: Natural history defined in a serially biopsied population over a 20-year period // Ann. Oncol. Oxford University Press (OUP), 1995. Vol. 6, № 3. P. 249–256.
  22. Воробьев В.И. et al. Мантийноклеточная лимфома: программное лечение первичных больных в возрасте до 65 лет // Клиническая онкогематология. 2013. Vol. 6, № 3. P. 274–281.
  23. Ferrer A. et al. Central nervous system involvement in mantle cell lymphoma // Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. Ann Oncol, 2008. Vol. 19, № 1. P. 135–141.
  24. Воробьев В.И., Тумян Г.С. Лимфома из клеток мантии // Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. 2018. P. 68–80.
  25. Zelenetz A.D. et al. B-cell lymphomas. NCCN Clinical Practice Guidelines in Oncology. Version 5.2022. 2022.
  26. Dreyling M. et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Ann. Oncol. 2017. Vol. 28, № Supplement 4. P. iv62–iv71.
  27. Remstein E.D. et al. Diagnostic utility of fluorescence in situ hybridization in mantle-cell lymphoma // Br. J. Haematol. Br J Haematol, 2000. Vol. 110, № 4. P. 856–862.
  28. Ramírez P., Valencia M., Torres A. Bronchoalveolar lavage to diagnose respiratory infections // Semin. Respir. Crit. Care Med. Semin Respir Crit Care Med, 2007. Vol. 28, № 5. P. 525–533.
  29. Gill S. et al. [18F]Fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma // Clin. Lymphoma Myeloma. Cancer Information Group, LP, 2008. Vol. 8, № 3. P. 159–165.
  30. Sun T. et al. Fluorescence in situ hybridization: method of choice for a definitive diagnosis of mantle cell lymphoma. // Am. J. Hematol. 2003. Vol. 74, № 1. P. 78–84.
  31. Alavi A. et al. Fluorodeoxyglucose-positron-emission tomography findings in mantle cell lymphoma // Clin. Lymphoma, Myeloma Leuk. 2011. Vol. 11, № 3. P. 261–266.
  32. Cheminant M. et al. Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study. // Haematologica. 2016. Vol. 101, № 3. P. 336–345.
  33. Королева Д.А., Щецова О.О., Звонков Е.Е. «Протокол диагностики и лечения больных лимфомой из клеток мантии» // Алгоритмы диагностики и протоколы лечения заболеваний системы крови под редакцией Е.Н. Паровичниковой. 2024. P. 132–160.
  34. Howard O.M. et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not predictive of progression-free survival // J. Clin. Oncol. 2002. Vol. 20, № 5. P. 1288–1294.
  35. LaCasce A.S. et al. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. // Blood. 2012. Vol. 119, № 9. P. 2093–2099.
  36. Lenz G. et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantiy improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: Results o // J. Clin. Oncol. 2005. Vol. 23, № 9. P. 1984–1992.
  37. Hoster E., Kluin-Nelemans H., Hermine O. Rituximab Maintenance after First-Line Immunochemotherapy in Mantle Cell Lymphoma: Long-Term Follow-up of the Randomized European MCL Elderly Trial // Blood (ASH Annu. Meet. Abstr. 2017. Vol. 130, № Suppl 1. P. Abstract 153.
  38. Bernstein S.H. et al. A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213 // Ann. Oncol. 2013. Vol. 24, № 6. P. 1587–1593.
  39. Д.А. К. et al. Негативное влияние мутаций в гене ТР53 на эффективность терапии лимфомы из клеток мантии. Промежуточные результаты протокола «ЛКМ-2016». // Гематология и трансфузиология. 2019. Vol. 64, № 3. P. 256–273.
  40. Damon L.E. et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909 // J. Clin. Oncol. 2009. Vol. 27, № 36. P. 6101–6108.
  41. Dreyling M. et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. // Blood. 2005. Vol. 105, № 7. P. 2677–2684.
  42. Fenske T.S., Carreras T., Zhang M. Outcome of patients with mantle-cell lymphoma undergoing autologous versus reduced-intensity allogenic transplantation // Ann. Oncol. 2011. Vol. 22, № Suppl. 4. P. Abstract 018.
  43. Visco C. et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation // J. Clin. Oncol. 2013. Vol. 31, № 11. P. 1442–1449.
  44. Rummel M.J. et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial // Lancet. Elsevier Ltd, 2013. Vol. 381, № 9873. P. 1203–1210.
  45. Geisler C.H. Front-line therapy of mantle cell lymphoma // Haematologica. 2010. Vol. 95. P. 1241–1243.
  46. Kluin-Nelemans H.C. et al. Treatment of older patients with mantle-cell lymphoma // N. Engl. J. Med. Massachussetts Medical Society, 2012. Vol. 367, № 6. P. 520–531.
  47. Kahl B.S. et al. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: A pilot study from the Wisconsin Oncology Network // Ann. Oncol. 2006. Vol. 17, № 9. P. 1418–1423.
  48. Hilal T. et al. Rituximab maintenance therapy for mantle cell lymphoma: A systematic review and meta-analysis. // Am. J. Hematol. 2018. Vol. 93, № 10. P. 1220–1226.
  49. Rule S. et al. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies. // Br. J. Haematol. 2017. Vol. 179, № 3. P. 430–438.
  50. Ruan J. et al. Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma // Blood. 2018. Vol. 132, № 19. P. 2016–2025.
  51. Звонков Е.Е. et al. Комбинация ибрутиниба и венетоклакса с последующей терапией Т-клетками с химерным антигенным рецептором в первой линии лечения у пожилого больного лимфомой из клеток мантии с гиперлейкоцитозом и мутацией в гене TP53 // Гематология и трансфузиология. 2022. Vol. 67, № 3. P. 441–452.
  52. Jurczak W. et al. First-line ibrutinib + venetoclax treatment for mantle cell lymphoma in older patients or those with TP53 mutation: a new open-label arm of the phase 3 PCYC-1143 SYMPATICO STUDY // Wiley. 2018. P. 350–351.
  53. Jain P. et al. Acalabrutinib with rituximab as first-line therapy for older patients with mantle cell lymphoma - a phase II clinical trial // Blood. 2023. Vol. 142. P. 3036–3038.
  54. Dreyling M. et al. A Phase III Study of Zanubrutinib Plus Rituximab Versus Bendamustine Plus Rituximab in Transplant-Ineligible , Untreated Mantle Cell Lymphoma A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible , un // Futur. Oncol. 2021. Vol. 17, № 3. P. 255–262.
  55. Romaguera J.E. et al. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma // Br. J. Haematol. 2010. Vol. 150, № 2. P. 200–208.
  56. Martin P. et al. Outcome of deferred initial therapy in mantle-cell lymphoma // J. Clin. Oncol. 2009. Vol. 27, № 8. P. 1209–1213.
  57. Weigert O. et al. High Dose Cytarabine Salvage Regimen Combined with Bortezomib Is Feasible and Highly Effective in Relapsed Mantle Cell Lymphoma. // Blood. 2006. Vol. 108, № 11. P. 2449–2449.
  58. Dreyling M. et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma ( TRIANGLE ): a three-ar // Lancet Oncol. 2024. Vol. 403. P. 2293–2306.
  59. Д.А. К. et al. Первый опыт трансплантации аллогенных гемопоэтических стволовых клеток у больных лимфомой из клеток мантии с мутациями в гене ТР53. // Гематология и трансфузиология. 2020. Vol. 65, № 4. P. 483–500.
  60. Munshi P.N. et al. American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies // Transplant. Cell. Ther. 2021. Vol. 27, № 9. P. 720–728.
  61. Kumar A. et al. A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in patients with treatment-naïve, TP53-mutant mantle cell lymphoma // Blood. The American Society of Hematology, 2023. Vol. 142. P. 738–740.
  62. Королева Д.А. «Молекулярно-генетическая диагностика и терапия прогностически неблагоприятных форм лимфомы из клеток мантии» // Диссертация на соискание ученой степени кандидата медицинских наук. 2021.
  63. Robak T. et al. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma // Cancer. 2006. Vol. 107, № 7. P. 1542–1550.
  64. Coleman M. et al. Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy. // Cancer. 2008. Vol. 112, № 10. P. 2228–2232.
  65. Le Gouill S. et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma // N. Engl. J. Med. 2017. Vol. 377, № 13. P. 1250–1260.
  66. Hermine O. et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma N // Lancet. 2016. Vol. 388, № 10044. P. 565–575.
  67. Pott C. et al. R-CHOP/R-DHAP Compared to R-CHOP Induction Followed by High Dose Therapy with Autologous Stem Cell Transplantation Induces Higher Rates of Molecular Remission In MCL: Results of the MCL Younger Intergroup Trial of the European MCL Network // Blood. 2010. Vol. 116, № 21.
  68. Merli F. et al. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. // Br. J. Haematol. 2012. Vol. 156, № 3. P. 346–353.
  69. Geisler C.H. et al. Nordic MCL2 trial update: Six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: Still very long survival but late relapses do occur // Br. J. Haematol. 2012. Vol. 158, № 3. P. 355–362.
  70. Eskelund C.W. et al. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau // Br. J. Haematol. 2016. Vol. 175, № 3. P. 410–418.
  71. Le Gouill S. et al. Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial // Blood. 2021. Vol. 137, № 7. P. 877–887.
  72. Hawkes E.A. et al. Traverse: A Phase 2, Open-Label, Randomized Study of Acalabrutinib in Combination with Venetoclax and Rituximab in Patients with Treatment-Naive Mantle Cell Lymphoma // Blood. The American Society of Hematology, 2023. Vol. 142. P. 3054.
  73. Wang M. et al. Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma : 2-year safety and ef fi cacy analysis // BLOOD Adv. The American Society of Hematology, 2024. Vol. 8, № 17. P. 4539–4548.
  74. Kim A.I. et al. Phase I Safety and Preliminary Efficacy of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Austin // Blood. The American Society of Hematology, 2023. Vol. 142, № November. P. 3031.
  75. Hoster E., Pott C. Minimal residual disease in mantle cell lymphoma: Insights into biology and impact on treatment // Hematology. 2016. Vol. 2016, № 1. P. 437–445.
  76. Gatt M.E., Grisaro S. Central nervous system prophylaxis in mantle cell lymphoma // Blood. American Society of Hematology, 2009. Vol. 114, № 26. P. 5402–5403.
  77. Crocchiolo R. et al. Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients // Haematologica. Ferrata Storti Foundation, 2015. Vol. 100, № 10. P. e423–e427.
  78. Lin R.J. et al. Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations // Br. J. Haematol. 2019. Vol. 184, № 6. P. 1006–1010.
  79. Yan G. et al. A Phase II Study of Zanubrutinib-Based Induction and Maintenance Therapy in Young and Fit Patients with Untreated Mantle Cell Lymphoma (BRIDGE): An Updated Analysis with Long-Term Follow up // Blood. The American Society of Hematology, 2021. Vol. 142, № November. P. 6147–6148.
  80. Hawkes E. et al. A Window Study of Acalabrutinib Plus Rituximab Followed By R-Dhaox (rituximab, dexamethasone, cytarabine, oxaliplatin) and Autologous Stem Cell Transplant (ASCT) in Fit Mantle Cell Lymphoma (MCL): The Australasian Leukaemia & Lymphoma Group (ALLG) NHL33 W // Blood. 2021. Vol. 138. P. 4516.
  81. Soubeyran P., Gressin R. Treatment of the elderly patient with mantle cell lymphoma // Hematol. (United States). 2016. Vol. 2016, № 1. P. 425–431.
  82. Flinn I.W. et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study // Blood. American Society of Hematology, 2014. Vol. 123, № 19. P. 2944–2952.
  83. Gressin R. et al. Frontline Therapy with the Ribvd Regimen Elicits High Clinical and Molecular Response Rates and Long PFS in Elderly Patients Mantle Cell Lymphoma (MCL); Final Results of a Prospective Phase II Trial By the Lysa Group // Blood. 2014. Vol. 124, № 21. P. 148–148.
  84. Robak T. et al. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: // Lancet Oncol. 2018. Vol. 19, № 11. P. 1449–1458.
  85. Tisi M.C. et al. Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL // BLOOD Adv. The American Society of Hematology, 2023. Vol. 7, № 15. P. 3916–3924.
  86. Ruan J. et al. Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma // N. Engl. J. Med. N Engl J Med, 2015. Vol. 373, № 19. P. 1835–1844.
  87. Kluin-Nelemans H.C. et al. Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial // J. Clin. Oncol. 2020. Vol. 38, № 3. P. 248–256.
  88. Jain P. et al. Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma // Journal of Clinical Oncology. 2022. Vol. 40, № 2. P. 202–212.
  89. Visco C. et al. Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Older Patients with Mantle Cell Lymphoma: A Phase 2 Study By the Fondazione Italiana Linfomi (FIL) // Blood. 2023. Vol. 142. P. 737–740.
  90. Dreyling M. et al. Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations // Leuk. Lymphoma. Taylor and Francis Ltd, 2018. Vol. 59, № 8. P. 1814–1828.
  91. Chen R.W. et al. RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106 // Br. J. Haematol. 2017. Vol. 176, № 5. P. 759–769.
  92. Bega G. et al. Rituximab and Bendamustine ( BR ) Compared with Rituximab ,. 2021.
  93. Friedberg J.W. et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma // Blood. Blood, 2011. Vol. 117, № 10. P. 2807–2812.
  94. Wang M. et al. Phase 2 Trial of Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus Methotrexate- Cytarabine for Relapsed or Refractory Aggressive Mantle Cell Lymphoma // Cancer. 2008. Vol. 113, № 10. P. 2734–2741.
  95. Bonnet C. et al. Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas : Results of a Phase 1b-II Study of the LYSA Group // Cancers (Basel). 2022. Vol. 14, № 1761. P. 1–14.
  96. Wang M. et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial // Lancet. Elsevier Ltd, 2018. Vol. 391, № 10121. P. 659–667.
  97. Telford C. et al. Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma // Clin. Ther. Excerpta Medica Inc., 2019. Vol. 41, № 11. P. 2357-2379.e1.
  98. Song Y. et al. Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton’s Tyrosine Kinase // Clin. Cancer Res. Clin Cancer Res, 2020. Vol. 26, № 16. P. 4216–4224.
  99. Tam C.S. et al. Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma // Blood Adv. Blood Adv, 2021. Vol. 5, № 12. P. 2577–2585.
  100. Wang M.L. et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma // N. Engl. J. Med. Massachussetts Medical Society, 2013. Vol. 369, № 6. P. 507–516.
  101. Wang M.L. et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: Updated safety and efficacy results // Blood. American Society of Hematology, 2015. Vol. 126, № 6. P. 739–745.
  102. Dreyling M. et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: An international, randomised, open-label, phase 3 study // Lancet. Elsevier Ltd, 2016. Vol. 387, № 10020. P. 770–778.
  103. Wang M.L. et al. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. // Lancet. Oncol. 2016. Vol. 17, № 1. P. 48–56.
  104. Gironella M. et al. Rituximab Plus Gemcitabine and Oxaliplatin As Salvage Therapy in Patients with Relapsed/Refractory Mantle-Cell Lymphoma // Blood. 2012. Vol. 120, № 21.
  105. Corazzelli G. et al. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin’s lymphoma: Results of a pilot study // Annals of Oncology. 2006. Vol. 17, № SUPPL. 4.
  106. Trněný M. et al. Lenalidomide versus investigator’s choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): A phase 2, randomised, multicentre trial // Lancet Oncol. 2016. Vol. 17, № 3. P. 319–331.
  107. Chong E.A. et al. Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas. // Clin. Cancer Res. 2015. Vol. 21, № 8. P. 1835–1842.
  108. Davids M.S. et al. Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study // Clin. Cancer Res. Clin Cancer Res, 2021. Vol. 27, № 17. P. 4690–4695.
  109. Davids M.S. et al. Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma // https://doi.org/10.1200/JCO.18.00359. American Society of Clinical Oncology, 2018. Vol. 36, № 35. P. 3525–3527.
  110. Tam C.S. et al. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma // N. Engl. J. Med. 2018. Vol. 378, № 13. P. 1211–1223.
  111. Wang M. et al. Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study // J. Hematol. Oncol. BioMed Central, 2021. Vol. 14, № 1. P. 1–8.
  112. Jerkeman M. et al. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial // Lancet Haematol. 2018. Vol. 5, № 3. P. e109–e116.
  113. Jerkeman M. et al. Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase Ib-II Trial // Blood. American Society of Hematology, 2022. Vol. 140, № Supplement 1. P. 184–185.
  114. Le Gouill S. et al. Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: A multicenter experience // Ann. Oncol. 2012. Vol. 23, № 10. P. 2695–2703.
  115. Wang M. et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma // N. Engl. J. Med. 2020. Vol. 382, № 14. P. 1331–1342.
  116. Visco C. et al. Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study // Leukemia. Leukemia, 2021. Vol. 35, № 3. P. 787–795.
  117. Eyre T.A. et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy // Haematologica. 2019. Vol. 104, № 2. P. e68–e71.
  118. Zhao S. et al. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients // Am. J. Hematol. 2020. Vol. 95, № 6. P. 623–629.
  119. McCulloch R. et al. Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy // Br. J. Haematol. 2020. P. 1–5.
  120. McCulloch R. et al. Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients // Br. J. Haematol. Br J Haematol, 2021. Vol. 193, № 2. P. 290–298.
  121. Martin P. et al. Postibrutinib outcomes in patients with mantle cell lymphoma // Blood. Blood, 2016. Vol. 127, № 12. P. 1559–1563.
  122. Jain P. et al. Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib // Am. J. Hematol. Am J Hematol, 2021. Vol. 96, № 5. P. E137–E140.
  123. Dietrich S. et al. Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT) // Ann. Oncol. 2014. Vol. 25, № 5. P. 1053–1058.
  124. Wang M. et al. Long-Term Follow-up of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma // Blood. American Society of Hematology, 2018. Vol. 132, № Supplement 1. P. 2876–2876.
  125. Song Y. et al. ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA // Hematol. Oncol. John Wiley & Sons, Ltd, 2019. Vol. 37. P. 45–46.
  126. Wang M. et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial // Lancet. Oncol. Lancet Oncol, 2012. Vol. 13, № 7. P. 716–723.
  127. Goy A. et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: Phase II MCL-001 (EMERGE) study // J. Clin. Oncol. 2013. Vol. 31, № 29. P. 3688–3695.
  128. Witzig T.E. et al. Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma // Am. J. Hematol. Am J Hematol, 2017. Vol. 92, № 10. P. E575–E583.
  129. Robinson K.S. et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma // J. Clin. Oncol. J Clin Oncol, 2008. Vol. 26, № 27. P. 4473–4479.
  130. Rummel M. et al. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. // Lancet. Oncol. 2016. Vol. 17, № 1. P. 57–66.
  131. Fisher R.I. et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma // J. Clin. Oncol. J Clin Oncol, 2006. Vol. 24, № 30. P. 4867–4874.
  132. Goy A. et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study // Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. Ann Oncol, 2009. Vol. 20, № 3. P. 520–525.
  133. Sawalha Y. et al. A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma // BLOOD Adv. The American Society of Hematology, 2023. Vol. 7, № 13. P. 2983–2993.
  134. Tam C.S. et al. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma // Blood. 2009. Vol. 113, № 18. P. 4144–4152.
  135. Maris M.B. et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma // Blood. 2004. Vol. 104, № 12. P. 3535–3542.
  136. Marangon M. et al. Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell Therapy // Cancers (Basel). Cancers (Basel), 2021. Vol. 13, № 2. P. 1–21.
  137. Барях Е.А., Мякова Н.В., Поддубная И.В. Профилактика и лечение синдрома лизиса опухоли // Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. 2018. P. 251–253.
  138. Барях Е.А. et al. Лейкоз/лимфома Беркитта: клинические особенности, диагностические критерии, терапевтическая тактика // Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2010. Vol. 3, № 2. P. 138–143.
  139. Троицкая В.В. et al. Гиперлейкоцитоз, профилактика и лечение синдрома лизиса опухоли у пациентов с гематологическими заболеваниями // Сопроводительная терапия при лечении заболевай системы крови. Под редакцией Е.Н. Паровичниковой, Г.М. Галстян. 2024. P. 35–59.
  140. Narum S., Westergren T., Klemp M. Corticosteroids and risk of gastrointestinal bleeding: A systematic review and meta-analysis // BMJ Open. 2014. Vol. 4, № 5. P. e004587.
  141. Burget D.W., Chiverton S.G., Hunt R.H. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression // Gastroenterology. Gastroenterology, 1990. Vol. 99, № 2. P. 345–351.
  142. Ивашкин В.Т. et al. Диагностика и лечение язвенной болезни у взрослых (Клинические рекомендации Российской гастроэнтерологической ассоциации, Российского общества колоректальных хирургов и Российского эндоскопического общества). // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020. Vol. 30, № 1. P. 49–70.
  143. Scally B. et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials // Lancet Gastroenterol. Hepatol. Elsevier Ltd, 2018. Vol. 3, № 4. P. 231–241.
  144. Владимирова Л.Ю. et al. Практические рекомендации по профилактике и лечению тошноты и рвоты у онкологических больных // Практические рекомендации Российского общества клинической онкологии. Лекарственное лечение злокачественных опухолей. Поддерживающая терапия в онкологии. 2018. P. 502–511.
  145. Navari R.M., Gray S.E., Kerr A.C. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial // J. Support. Oncol. J Support Oncol, 2011. Vol. 9, № 5. P. 188–195.
  146. Navari R.M., Aapro M. Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting // N. Engl. J. Med. New England Journal of Medicine (NEJM/MMS), 2016. Vol. 374, № 14. P. 1356–1367.
  147. Roy V. et al. Hematopoietic Growth Factors. NCCN Guidelines. Ver 1.2022. 2022.
  148. SPIRIN M., GALSTYAN G., DROKOV M. Central venous access in lymphoma patients (pts) with superior vena cava syndrome (SVCS) // INTENSIVE CARE Med. Exp. 2019. Vol. 7, № Suppl. 3:001341. P. 388–389.
  149. Константинова Т.С., Клясова Г.А., Капланов К.Д. Лечение и профилактика инфекционных осложнений у пациентов с лимфопролиферативными заболеваниями. // Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. 2018. P. 289–311.
  150. Srivastava S., Wood P. Secondary antibody deficiency-causes and approach to diagnosis // Clin. Med. J. R. Coll. Physicians London. 2016.
  151. Сомонова О.В. et al. Практические рекомендации по профилактике и лечению тромбоэмболических осложнений у онкологических больных // Злокачественные опухоли: Практические рекомендации RUSSCO. 2021. Vol. 11, № 3S2. P. 47.
  152. Lyman G.H. et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer // Blood Adv. Blood Adv, 2021. Vol. 5, № 4. P. 927–974.
  153. Семиглазова Т.Ю. et al. Практические рекомендации по лечению и профилактике мукозитов // Злокачественные опухоли: Практические рекомендации RUSSCO. 2021. Vol. 11, № 3s2. P. 51.
  154. Peterson D.E., Bensadoun R.J., Roila F. Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines // Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. Ann Oncol, 2011. Vol. 22 Suppl 6, № Suppl 6.
  155. Сытов А.В., Лейдерман И.Н., Ломидзе С.В., Нехаев И.В. Х.А.Ж.. Практические рекомендации по нутритивной поддержке онкологических больных // RUSSCO. 2017. P. 524–532.
  156. de van der Schueren M.A.E. et al. Systematic review and meta-analysis of the evidence for oral nutritional intervention on nutritional and clinical outcomes during chemo(radio)therapy: current evidence and guidance for design of future trials // Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. Ann Oncol, 2018. Vol. 29, № 5. P. 1141–1153.
  157. Oktay K. et al. Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update // J. Clin. Oncol. J Clin Oncol, 2018. Vol. 36, № 19. P. 1994–2001.
  158. Meirow D., Nugent D. The effects of radiotherapy and chemotherapy on female reproduction // Hum. Reprod. Update. 2001. Vol. 7, № 6. P. 535–543.
  159. Галстян Г.М. Инфузионная терапия у пациентов с гематологическими заболеваниями // Сопроводительная терапия при лечении заболеваний системы крови. Под редакцией Е.Н. Паровичниковой, Г.М. Галстян. 2024. P. 495–501.
  160. Камельских Д.В. et al. Трансфузии донорской крови и (или) ее компонентов у взрослых пациентов с гематологическими заболеваниями. // Сопроводительная терапия при лечении заболеваний системы крови. Под редакцией Е.Н. Паровичниковой, Г.М. Галстяна. ИД «Практика». 2024. P. 387–407.
  161. Галстян Г.М., Спирин М.В. Сосудистый доступ в гематологии // ИД “Практика.” 2021. P. 232.
  162. Воробьев А.И. et al. Критические состояния при гемобластозах (типичные формы и выживаемость в условиях отделения реанимации). // Терапевтический архив. 1993. Vol. 65, № 7. P. 3–6.
  163. Галстян Г.М., Городецкий В.М. Опыт работы отделения реанимации и интенсивной терапии ФГБУ ГНЦ МЗиСР РФ // Клиническая онкогематология. 2011. Vol. 4, № 1. P. 75–78.
  164. Cheson B.D. et al. Revised response criteria for malignant lymphoma // Journal of Clinical Oncology. 2007. Vol. 25, № 5. P. 579–586.
  165. Paul K.L. Rehabilitation and exercise considerations in hematologic malignancies. // Am. J. Phys. Med. Rehabil. 2011. Vol. 90, № 5 Suppl 1. P. S88-94.
  166. Yelvington B.J. Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma. // J. Adv. Pract. Oncol. Harborside Press, 2018. Vol. 9, № 5. P. 530–534.
  167. Davies A. et al. Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development // Advances in Therapy. Springer Healthcare, 2017. Vol. 34, № 10. P. 2210–2231.
  168. García‐Muñoz R. et al. Safety of switching from intravenous to subcutaneous rituximab during first‐line treatment of patients with non‐Hodgkin lymphoma: the Spanish population of the MabRella study // Br. J. Haematol. Blackwell Publishing Ltd, 2020. Vol. 188, № 5. P. 661–673.
  169. Macdonald D. et al. A canadian perspective on the subcutaneous administration of rituximab in non-Hodgkin lymphoma // Current Oncology. Multimed Inc., 2017. Vol. 24, № 1. P. 33–39.
  170. Delarue R. et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: A phase 2 study from the Groupe d’Etude des Lymphomes de l’Adulte // Blood. 2013. Vol. 121, № 1. P. 48–53.
  171. Geisler C.H. et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: A nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group // Blood. 2008. Vol. 112, № 7. P. 2687–2693.
  172. Dreyling M., Ferrero S., Hermine O. How to manage mantle cell lymphoma // Leukemia. Nature Publishing Group, 2014. Vol. 28, № 11. P. 2117–2130.
  173. Sawalha Y. et al. Ef fi cacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma , a Single-Institution Experience // Clin. Lymphoma, Myeloma Leuk. Elsevier Inc., 2017. P. 1–8.
  174. Olivieri A. et al. Proposed definition of “poor mobilizer” in lymphoma and multiple myeloma: An analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo // Bone Marrow Transplant. Bone Marrow Transplant, 2012. Vol. 47, № 3. P. 342–351.
  175. Yang B.B., Kido A. Pharmacokinetics and pharmacodynamics of pegfilgrastim // Clinical Pharmacokinetics. Clin Pharmacokinet, 2011. Vol. 50, № 5. P. 295–306.
  176. Costa L.J. et al. Pegfilgrastim-versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: Efficacy and cost analysis // Transfusion. Transfusion, 2012. Vol. 52, № 11. P. 2375–2381.
  177. Афанасьева О.И., Воинов В.А. Г.Ю.С. Экстракорпоральная гемокоррекция: терминология, языковые соответствия. СПб, 2016. P. 7–15.
  178. Sutherland D.R. et al. The ISHAGE guidelines for CD34+ cell determination by flow cytometry // Journal of Hematotherapy and Stem Cell Research. J Hematother, 1996. Vol. 5, № 3. P. 213–226.
  179. Enric Carreras D.C., Mohty Mohamad K.N. Hematopoietic Stem Cell Transplantation and Cellular Therapies. 2019. 702 p.
  180. Frankiewicz A. et al. Comparable safety profile of BeEAM (bendamustine, etoposide, cytarabine, melphalan) and BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning before autologous haematopoietic cell transplantation. // Contemp. Oncol. (Poznan, Poland). Termedia Publishing, 2018. Vol. 22, № 2. P. 113–117.
  181. Caballero M.D. et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors // Bone Marrow Transplant. Bone Marrow Transplant, 1997. Vol. 20, № 6.
  182. Galieni P. et al. Modified BEAM as a conditioning regimen for mantle cell lymphoma patients undergoing autologous hematopoietic stem cell transplantation // Ther. Adv. Hematol. 2024. Vol. 15. P. 1–4.
  183. Mills W. et al. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin’s lymphoma. // J. Clin. Oncol. J Clin Oncol, 1995. Vol. 13, № 3. P. 588–595.
  184. Colita A. et al. LEAM vs. BEAM vs. CLV Conditioning Regimen for Autologous Stem Cell Transplantation in Malignant Lymphomas. Retrospective Comparison of Toxicity and Efficacy on 222 Patients in the First 100 Days After Transplant, On Behalf of the Romanian Society for Bon // Front. Oncol. 2019. Vol. 9, № September. P. 1–10.
  185. Sharma A. et al. Comparison of BEAM vs. LEAM regimen in autologous transplant for lymphoma at AIIMS // Springerplus. 2013. Vol. 2, № 1. P. 1–6.
  186. Perz J.B. et al. LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin’s lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre. // Bone Marrow Transplant. Bone Marrow Transplant, 2007. Vol. 39, № 1. P. 41–47.
  187. Ramzi M. et al. Autologous noncryopreserved hematopoietic stem cell transplant with CEAM as a modified conditioning regimen in patients with Hodgkin lymphoma: a single-center experience with a new protocol. // Exp. Clin. Transplant. Exp Clin Transplant, 2012. Vol. 10, № 2. P. 163–167.
  188. Visani G. et al. XRCC1 399GG genotype predicts significantly longer overall survival in resistant lymphoma patients treated with Benda-EAM and ASCT // Bone Marrow Transplant. Nature Publishing Group, 2020. Vol. 55, № 4. P. 818–820.
  189. Visani G. et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. // Blood. 2011. Vol. 118, № 12. P. 3419–3425.
  190. Шкляев С.С., Павлов В.В. Лимфома Ходжкина и «новый старый» бендамустин // Клиническая онкогематология. 2013. Vol. 6, № 2. P. 139–147.
  191. Keil F. et al. BendaEAM versus BEAM as conditioning regimen for ASCT in patients with relapsed lymphoma ( BEB ): a multicentre , randomised , phase 2 trial // Lancet. Elsevier Ltd, 2023. Vol. 66. P. 102318.
  192. Conn H.O., Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. // J. Intern. Med. J Intern Med, 1994. Vol. 236, № 6. P. 619–632.
  193. Протоколы трансплантации аллогенных гепомоэтических стволовых клеток. Под ред. В.Г. Савченко. М.: Практика, 2020. 320 p.
  194. Bonfim C. et al. Bone Marrow Transplantation (BMT) for heavily Transfused Patients (pts) with Severe Aplastic Anemia (SAA): 147 pts treated at the same institution with Busulfan (BU) + Cyclophosphamide (CY) // Biol. Blood Marrow Transplant. Elsevier, 2006. Vol. 12, № 2. P. 28.
  195. de Latour R.P., Risitano A.M., Dufour C. Severe Aplastic Anemia and PNH // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 579–587.
  196. Michonneau D., Socié G. GVHD Prophylaxis (Immunosuppression) // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 177–183.
  197. Nagler A., Shimoni A. Conditioning // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 99–109.
  198. Гаврилина О.А. et al. Терапия Т-клетками с химерным антигенным рецептором взрослых больных В-клеточными лимфопролиферативными заболеваниям // Гематология и трансфузиология. 2022. Vol. 6, № 1. P. 8–28.
  199. Wang M. et al. KTE-X19 CAR T-Cell therapy in relapsed or refractory mantle-cell lymphoma // N. Engl. J. Med. 2020. Vol. 382, № 14. P. 1331–1342.
  200. Schubert M. et al. Side-effect management of chimeric antigen receptor ( CAR ) T-cell therapy // Ann. Oncol. Elsevier Ltd., 2021. Vol. 32, № 1. P. 34–48.
  201. Santomasso B.D. et al. Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy : ASCO Guideline abstract // J. Clin. Oncol. 2021. Vol. 39, № 35. P. 3978–3992.
  202. Strati P. et al. Clinical e ffi cacy of anakinra to mitigate CAR T-cell therapy – associated toxicity in large B-cell lymphoma // Blood Adv. 2020. Vol. 4, № 13. P. 3123–3127.
  203. Christian H. Geisler, Arne Kolstad, Anna Laurell, Riikka Ra¨ty, Mats Jerkeman, Mikael Eriksson, Marie Nordstro¨m, Eva Kimby, Anne Marie Boesen, Herman Nilsson-Ehle, Outi Kuittinen, Grete F. Lauritzsen, Elisabeth Ralfkiær, Mats Ehinger, Christer Sundstro¨m and E.E. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT) // Nat. Rev. Immonology. 2010. Vol. 3, № 8. P. 875–885.
  204. Hoster E. et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma // Blood. 2008. Vol. 111, № 2. P. 558–565.
  205. Hoster E. et al. Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: Results from randomized trials of the european mantle cell lymphoma network // J. Clin. Oncol. 2016. Vol. 34, № 12. P. 1386–1394.
  206. Schaffel R. et al. Prognostic impact of proliferative index determined by quantitative image analysis and the international prognostic index in patients with mantle cell lymphoma // Ann. Oncol. 2010. Vol. 21, № 1. P. 133–139.
  207. Oken M.M. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group // Am. J. Clin. Oncol. 1982. Vol. 5, № 6. P. 649–655.
  208. Gratwohl A. The EBMT risk score // Bone Marrow Transplantation. Nature Publishing Group, 2012. Vol. 47, № 6. P. 749–756.
  209. Sorror M.L. et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. // Blood. The American Society of Hematology, 2005. Vol. 106, № 8. P. 2912–2919.
  210. Sorror M.L. et al. Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study // Biol. Blood Marrow Transplant. Elsevier Inc., 2015. Vol. 21, № 8. P. 1479–1487.

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*